Prospective study evaluating olfactometric and rhinomanometric outcomes in postmenopausal women on 1 mg 17β-estradiol and 2 mg drospirenone HT

被引:20
|
作者
Caruso, Salvatore [1 ,2 ]
Serra, Agostino [3 ]
Grillo, Calogero [3 ]
De Leo, Vincenzo [4 ]
Maiolino, Luigi [3 ]
Agnello, Carmela [2 ]
Cianci, Antonio [1 ]
机构
[1] Univ Catania, Dept Microbiol Sci & Gynecol Sci, Catania, Italy
[2] Univ Catania, Res Grp Sexol, Sect Dept Gynecol Sci, Catania, Italy
[3] Univ Catania, Dept Otorhinolaryngol, Catania, Italy
[4] Univ Siena, Dept Gynecol & Obstet, I-53100 Siena, Italy
关键词
drospirenone; hormone therapy; menopause; olfactometric threshold; rhinomanometry;
D O I
10.1097/gme.0b013e31816be973
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To evaluate the effects of drospirenone oil the olfactory sensitivity in postmenopausal women treated with hormone therapy (HT). Design: Forty-seven naturally postmenopausal women participated in the prospective study. The women Underwent continuous combined HT containing 1 mg 17 beta-estradiol and 2 mg drospirenone (DRSP). Airflow resistance values and olfactometric thresholds were measured by using rhinomanomety and olfactometry, respectively, performed at baseline and in the third and sixth cycle of HT. Results: Rhinomanometric values were better during 17 beta-estradiol/DRSP HT with respect to those observed at baseline (P < 0.001). Olfactometric threshold data indicated a higher sensitivity during both the third (P < 0.05), and sixth cycles of 17 beta-estradiol/DRSP HT (P < 0.001) than at baseline. Conclusions: Our study confirmed that the nasal airflow resistance and olfactory thresholds to odors may depend on steroid hormones. We believe that estrogens could influence neuronal plasticity and the neuronal conduction time in the olfactory system. The antimineralocorticoid activity of DRSP may produce a decrease in nasal edema, inducing a better interaction between odorous substances with receptors.
引用
收藏
页码:967 / 972
页数:6
相关论文
共 50 条
  • [21] 17β-estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women
    Stevenson, JC
    Teter, P
    Lees, B
    MATURITAS, 2001, 38 (02) : 197 - 203
  • [22] The Effects of Estradiol Valerate 2 mg and Dienogest 2 mg Combination on Activated Protein C Resistance in Healthy Postmenopausal Women
    Kafkas, Samet
    Kalkan, Nurdan Yidiz
    Bolaman, Zahit
    Kalkan, Uzeyir
    Odabasi, Ali R. Za
    Yuksel, Hasan
    Batun, Sabri
    Onur, Ergun
    JOURNAL OF THE TURKISH-GERMAN GYNECOLOGICAL ASSOCIATION, 2006, 7 (04) : 334 - 341
  • [23] A comparative 2-year study of the effects of sequential regimens of 1 mg 17β-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone on the bleeding profile and endometrial safety in postmenopausal women
    Koninckx, PR
    Spielmann, D
    GYNECOLOGICAL ENDOCRINOLOGY, 2005, 21 (02) : 82 - 89
  • [24] Effects of a combination of 2 mg estradiol valerate and 3 mg dienogest on coagulation, lipid profile, and glucose metabolism in postmenopausal women
    Gräser, T
    Müller, A
    Druckman, R
    Oettel, M
    DRUGS OF TODAY, 2001, 37 : 87 - 99
  • [25] Prospective study on sexual behavior of women using 30 μg ethinylestradiol and 3 mg drospirenone oral contraceptive
    Caruso, S
    Agnello, C
    Intelisano, G
    Farina, M
    Di Mari, L
    Sparacino, L
    Cianci, A
    CONTRACEPTION, 2005, 72 (01) : 19 - 23
  • [26] Efficacy on climacteric symptoms of a continuous combined regimen of 1 mg 17β-estradiol and trimegestone versus two regimens containing 1 or 2 mg 17β-estradiol and norethisterone acetate
    Gambacciani, M
    Spielmann, D
    Genazzani, AR
    GYNECOLOGICAL ENDOCRINOLOGY, 2005, 21 (02) : 65 - 73
  • [27] Pharmacokinetics of Estradiol Valerate 2mg + Dienogest 2mg (Climodien® 2/2) after Single and Repeated Oral Administration in Healthy Postmenopausal Women
    H. Zimmerman
    J. J. Thebault
    T. Duvauchelle
    A. Mignot
    A. Renoux
    V. Gualano
    Clinical Drug Investigation, 2000, 20 : 123 - 134
  • [28] Pharmacokinetics of estradiol valerate 2mg+dienogest 2mg (Climodien® 2/2) after single and repeated oral administration in healthy postmenopausal women
    Zimmerman, H
    Thebault, JJ
    Duvauchelle, T
    Mignot, A
    Renoux, A
    Gualano, V
    CLINICAL DRUG INVESTIGATION, 2000, 20 (02) : 123 - 134
  • [29] Drospirenone-estradiol lowers blood pressure and has potassium sparing effects in hypertensive postmenopausal (PM) women receiving hydrochlorothiazide (HCTZ) 25 mg daily
    Preston, Richard A.
    Norris, Paul M.
    Alonso, Alberto
    Hanes, Vladimir
    Karara, Adel
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2006, 13 (06): : 1010 - 1010
  • [30] The effect of 3-year treatment with 0.25 mg/day of micronized 17β-estradiol on cognitive function in older postmenopausal women
    Pefanco, Mary Ann
    Kenny, Anne M.
    Kaplan, Richard F.
    Kuchel, George
    Walsh, Stephen
    Kleppinger, Alison
    Prestwood, Karen
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2007, 55 (03) : 426 - 431